Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
BPC-15715 residuesGEPPPGKPADDAGLVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: BPC-157, BPC 157, Body Protection Compound
Over 180 PubMed papers and tens of thousands of user reports, but only about 30 humans formally studied. The BPC-157 peptide (Body Protection Compound-157) is a 15-amino-acid pentadecapeptide from human gastric juice. It has become the most discussed healing peptide online, with reliable community reports of accelerated tendon, ligament, and gut repair. Animal research backs the mechanism. The standard protocol (250 mcg subcutaneous twice daily near the injury) has been stable for years. Community evidence is strong; formal clinical proof is still catching up fast.
A 2025 systematic review by Vasireddi's group [1] screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were animal studies. One was clinical. That ratio says a lot about where the science stands right now. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. It promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendons and ligaments. One property separates it from most peptides: it survives stomach acid. Oral dosing works, particularly for gut applications, because the peptide reaches intestinal tissue without being degraded. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. On April 15, 2026, HHS Secretary Kennedy removed BPC-157 and 11 other peptides from Category 2. PCAC review begins July 2026, with compounding access projected for late 2026 to mid-2027. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.
BPC-157 works through several repair pathways at once. That overlap is part of why it turns up across so many injury models. The primary mechanism is angiogenesis. BPC-157 upregulates vascular endothelial growth factor (VEGF), triggering new blood vessel formation at injury sites. More capillaries mean better oxygen and nutrient delivery to damaged tissue. This effect is documented across multiple independent labs. BPC-157 also modulates nitric oxide synthesis, shifting the NO system toward tissue protection. In the gut, this translates to mucosal repair and reversal of NSAID-induced damage. Sikiric and colleagues mapped this pathway extensively [2]. For tendons and ligaments, BPC-157 activates the FAK-paxillin signaling cascade. This pathway controls how cells attach to the extracellular matrix and migrate into damaged areas. That process is rate-limiting in tendon healing. BPC-157 interacts with both dopamine and serotonin systems [3]. This dual modulation likely explains the neuroprotective effects in animal models and the neuropsychiatric side effects some users report at higher doses. Growth hormone receptor upregulation adds another layer. BPC-157 appears to sensitize tissues to circulating growth hormone, which may contribute to the tissue remodeling users describe.
Strong preclinical evidence across 180+ PubMed papers (tendons, ligaments, gut mucosa, nerves, muscle). Human data is extremely limited: ~30 subjects across all published studies. 2025 systematic review (Vasireddi et al.) found 35 preclinical + 1 clinical study from 544 screened. 2025 IV pilot (Lee & Burgess, n=2) showed tolerability up to 20 mg IV. 2024 intravesical interstitial cystitis series (n=12, 80-100% symptom resolution). No completed Phase II/III trial. No published oral bioavailability data in humans.
Vasireddi et al. 2025, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS J. PMID 40756949 / PMC12313605: screened 544 papers, 36 met inclusion, 35 preclinical + 1 clinical; consistent positive musculoskeletal outcomes across animal models; authors recommend caution given evidence quality
No completed Phase II/III human trials. Only ~30 humans formally studied in all published literature. >80% of PubMed records originate from Sikiric's group: limited independent replication. The only Phase I trial (NCT02465229) was withdrawn in 2016 before enrollment. Oral bioavailability never quantified in humans. IM bioavailability: 14-19% (rats) vs 45-51% (dogs): human figure unknown. Long-term safety unknown. FDA Category 2 classification (2023-2026) cited immunogenicity risk and insufficient characterization of peptide impurities in compounded preparations. BPC-157 was removed from Category 2 on April 15, 2026; PCAC review begins July 2026.
The most widely discussed healing peptide online. Standard protocol (250 mcg 2x/day SC near injury) dominates community consensus. Most users report measurable improvement in soft tissue injuries within 1-3 weeks. Gut healing via oral route (500-1,000 mcg fasted) frequently reported effective within days to 2 weeks. Side effects are real but polarized: most tolerate it well at standard doses; a meaningful minority report anxiety, panic attacks, and mood changes, especially above 500 mcg/day or with SSRI/SNRI use.
Science and community agree on core healing mechanisms (angiogenesis, collagen synthesis, gut repair). Divergence: community doses (250-500 mcg/day) were never validated in a human dose-finding trial. Community widely reports neuropsychiatric side effects (anxiety, panic, anhedonia) that barely appear in preclinical literature: animal models cannot self-report mood effects. The serotonin/dopamine modulation documented in animal studies (Sikiric et al. PMID 9073154) provides plausible mechanistic basis for community-reported mood effects.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250mcg | 2x Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 500mcg | 2x Daily |
All dosing is community-driven. No human dose-finding trial has been completed. The tiers: beginner 250 mcg twice daily, moderate 500 mcg once daily, aggressive 500 mcg twice daily. All subcutaneous. For gut healing, 500 mcg oral once daily on an empty stomach. Reconstitution: 5 mg vial with 2 mL bacteriostatic water gives 2.5 mg per mL. Each 10 units on a U-100 insulin syringe equals 250 mcg. A 10 mg vial with 2 mL: each 5 units equals 250 mcg. Add water along the vial wall; swirl, never shake. Inject as close to the injury as you can. For gut applications, take orally on an empty stomach and wait 30 minutes. Cycle 4 to 6 weeks on, 2 weeks off. Refrigerate reconstituted vials at 2 to 8 degrees Celsius; use within 3 to 4 weeks. BPC-157 is prohibited under WADA S0 in and out of competition.
Most users run 4-6 week cycles targeted at a specific injury. Can be repeated as needed after a brief break.
No established receptor desensitization mechanism for BPC-157. No published evidence of antibody formation in the limited human data. Cycling is precautionary: BPC-157 continuously stimulates angiogenesis (VEGF pathway), which could theoretically support tumor microvasculature in an oncologic context. Zero long-term human safety data exists. The 4-6 weeks on / 2 weeks off convention is entirely community-derived and not validated in any clinical trial.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced pain and inflammation Days 1-7. Improved range of motion Weeks 2-3. Significant functional recovery by Weeks 4-6 for most soft tissue injuries. Chronic tendinopathies may require 2-3 cycles.
Monitor: No bloodwork required at standard doses. Track pain (VAS 0-10) and range of motion weekly. If anxiety, palpitations, or mood changes develop, reduce to 1x/day or discontinue.
It worked — with pretty surprising speed, no less.
500mcg recommended dosage, 10 AM/PM daily, 8 weeks on / 8 weeks off.
7/12 patients reported relief lasting 6+ months from a single injection.
Gather: BPC-157 vial (5 mg or 10 mg lyophilized), bacteriostatic water, alcohol swabs, insulin syringes (29 to 31 gauge, U-100).
Draw 2 mL bacteriostatic water. Inject into the BPC-157 vial slowly along the glass wall; do not spray onto the powder. Swirl gently. Solution should be clear. Discard if cloudy.
Calculate your dose: 5 mg vial with 2 mL BAC water means 10 units equals 250 mcg. A 10 mg vial with 2 mL means 5 units equals 250 mcg.
Tap out air bubbles.
Inject subcutaneously: pinch skin near the injury at 45 degrees, insert, release pinch, inject slowly. For gut healing, squirt the dose under your tongue or swallow on an empty stomach.
For systemic abdominal dosing, alternate left and right lower abdomen.
Use within 3 to 4 weeks. Do not freeze.
Reference route: no adjustment needed; community doses (250-500 mcg) are based on SC
Near-injury injection for local effects; abdomen for systemic/gut. Human SC bioavailability unknown; IM bioavailability in rats 14-19%, dogs 45-51%.
Same dose as SC; IM Tmax faster (3 min rats, 8.67 min dogs vs. SC)
Less community-preferred than SC: SC is equally effective and less painful. No evidence IM outperforms SC for injury healing outcomes.
Community doses 500-1,000 mcg/day oral vs. 250-500 mcg/day SC: higher dose compensates for unquantified oral bioavailability loss
BPC-157 is uniquely acid-stable among peptides: survives gastric transit. Oral bioavailability has never been quantified in humans or published animal PK studies. For gut healing, direct mucosal contact is part of the mechanism. For musculoskeletal injury, SC remains preferred.
2025 pilot: 10-20 mg IV in clinical setting: far above community SC doses; not applicable to self-use protocols
Lee & Burgess 2025 (PMID 40131143): n=2 healthy adults, up to 20 mg IV over 1 hour, no adverse events, no biomarker changes. Clinical-only route. Risk of infection, air embolism, and anaphylaxis precludes self-administration.
BPC-157 provides targeted local repair at the injury site; TB-500 acts systemically to reduce inflammation and drive cell migration body-wide. Together they cover local + systemic healing: the "Wolverine Stack." Most popular injury-recovery combination in the peptide community.
BPC-157 250-500 mcg/day SC near injury + TB-500 2.5 mg 2x/week SC anywhere. 4-8 weeks loading, then half-frequency maintenance.
GHK-Cu promotes collagen synthesis, skin healing, and anti-aging tissue remodeling. Stacked with BPC-157 to optimize quality of new collagen and reduce scarring during structural repair.
BPC-157 250 mcg 2x/day SC near injury + GHK-Cu 1-2 mg/day SC. GHK-Cu sometimes used topically at wound site alongside systemic BPC-157.
Ipamorelin pulses growth hormone, augmenting systemic anabolic and tissue repair capacity. Community rationale: BPC-157 targets the injury locally; ipamorelin elevates the GH environment for faster overall recovery. No human combination data exists.
BPC-157 250 mcg 2x/day SC + Ipamorelin 200-300 mcg SC 30-60 min pre-sleep.
BPC-157 modulates serotonin and dopamine pathways (Sikiric et al. PMID 9073154). Multiple community reports document worsened anxiety, agitation, and mood instability when combining with antidepressants. No human interaction study exists. Mechanistic basis is plausible; risk is not quantified.
BPC-157 may modulate coagulation pathways (noted in peptides.ts drugInteractions). Potential additive effect on bleeding risk with anticoagulants. No human evidence; precautionary.
Anti-VEGF drugs mechanistically oppose BPC-157's primary angiogenic action (VEGF upregulation). Combining is pharmacologically contradictory and would likely reduce therapeutic effect of both.
Do not combinePricing updated 2026-04-09
About 30 humans have been formally studied across all BPC-157 publications combined. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much. At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs. Anxiety and panic attacks are the most commonly reported serious community side effects. BPC-157 modulates both dopamine and serotonin systems in animal studies (Sikiric and colleagues)[3]. Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect. Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week. Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses. Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing. Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 vendors; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination. Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber.
Verify BPC-157 dosing and safety with a second opinion
Research-only market with no pharmaceutical manufacturing oversight. Compounding legally prohibited in the US (FDA Category 2 from 2023 to April 2026; removed April 15, 2026; PCAC review pending). All sources are research-grade vendors. Independent purity testing (Finnrick Analytics, 450 samples across 64 vendors) found purity ranging from 82% to 100%: significant variability. FDA concerns on file include peptide impurities, inadequate characterization, and immunogenicity risk from inconsistent synthesis. Budget vendors carry the highest quality risk.
| Test | When | Target |
|---|---|---|
| Injury functional assessment (pain VAS + range of motion) | Weekly throughout active cycle | Progressive improvement; VAS pain <3/10 by end of cycle for successful outcomes |
| Mood and anxiety self-assessment | Daily during first 2 weeks, then weekly | No clinically meaningful change from baseline. Any worsening triggers dose reduction or discontinuation. |
| Basic Metabolic Panel (BMP) + CBC | Baseline + Week 4 for users running >500 mcg/day or multiple consecutive cycles | Within normal reference ranges |
Healing progress is the primary outcome. No biomarker confirms tendon/ligament healing in a community setting: pain scale and functional assessment are the practical endpoints.
BPC-157 modulates serotonin and dopamine pathways. Anxiety, panic, anhedonia, and mood changes are the most common serious adverse effects. Early detection prevents prolonged side-effect exposure.
No evidence-based requirement exists. Precautionary given zero long-term human safety data. The 2025 IV pilot (Lee & Burgess, n=2) found no changes in cardiac, hepatic, renal, thyroid, or glucose markers: but this was n=2 over 2 days, not sustained community-use dosing.
Peptide begins modulating nitric oxide and growth factor pathways. No visible changes yet. Reduced pain at injury site reported anecdotally.
Early healing response underway. Reduced inflammation and pain around injury. Gut-related improvements (reduced bloating, discomfort) may begin.
Noticeable improvement in tendon/ligament mobility and pain levels. Gut lining repair progressing. Angiogenesis supporting tissue remodeling.
Significant functional recovery for most soft tissue injuries. Gut symptoms substantially improved. End of typical cycle: assess and consider a 2-week break before repeating.
Days 1 to 3: BPC-157 begins modulating nitric oxide and growth factor pathways. Plasma half-life is under 30 minutes, but functional tissue activity lasts roughly 4 hours. Most users notice nothing visible yet. Some report subtle pain reduction near the injection area within a day or two. That is likely an analgesic effect from NO modulation, not structural healing. Weeks 1 to 2: Inflammation and pain around the injury typically decrease. Gut protocol users often notice the first improvement during this window (reduced bloating, less discomfort). Most first-cycle side effects (palpitations, nausea) have resolved by end of week 2. Anxiety and mood effects, where they occur, tend to peak here. Weeks 3 to 4: Functional improvement becomes noticeable. Tendon and ligament mobility improves; pain continues to drop. Gut users report sustained symptom control. The angiogenesis triggered in earlier weeks is now supporting active tissue remodeling. Weeks 5 to 6: Most users with soft tissue injuries report meaningful functional recovery. Gut symptoms are typically well controlled. End of a standard cycle. Take a minimum 2-week break. Chronic tendinopathies or severe injuries may need 2 to 3 cycles total.
Nitric oxide modulation begins within hours of first dose. VEGF upregulation and FAK-paxillin pathway activation initiated. ERK1/2 phosphorylation and AKT expression elevated in preclinical models. No measurable structural repair yet.
Subjective pain reduction often reported within 24-48 hours: likely analgesic/NO effect rather than structural healing. Many users notice improved sleep quality at the injury site. First-injection anxiety and palpitations peak in this window.
Anti-inflammatory cytokine suppression (COX-2, IL-6, TNF-α). Angiogenesis begins: new capillary formation at injury site. Gut mucosal repair accelerates for oral protocols (direct mucosal contact).
Reduced swelling and tenderness at injury. Gut users report bloating and discomfort improvement. Most side effects (palpitations, nausea) have resolved or become manageable by end of Week 2.
Angiogenesis drives improved nutrient delivery to damaged tissue. Collagen synthesis and tendon fibroblast activity elevated. Growth hormone receptor upregulation in tendon fibroblasts (PMC6271067) amplifies repair signaling.
Noticeably improved range of motion. Significant pain reduction with movement. Many users return to light training. Gut protocol users often report near-complete resolution of chronic GI symptoms.
Peak angiogenic benefit achieved. Structural tissue integrity improved. Animal studies show healed tissue approaches normal tensile strength at 6 weeks.
Most users report functional recovery for soft tissue injuries. Athletes return to sport. End of standard cycle: 2-week break recommended. Chronic or severe injuries may require a second cycle.
No continued pharmacological activity after clearance. Angiogenesis maturation may continue passively: new capillaries established during the cycle continue to support tissue without further peptide stimulus.
Majority report no regression during off-cycle. Some note continued improvement after stopping: consistent with angiogenesis maturation lag. Re-injury risk assessment before returning to full training load.
Source: Animal PK data: t1/2 <30 min IV/IM in rats and dogs (He et al., Front Pharmacol 2022, PMID 36588717). Functional duration ~4 hours likely reflects tissue-level activity, not plasma half-life.
Loading the interactive decay curve.
BPC-157 has no FDA approval for any indication. In the United States it is classified as a research chemical and cannot be marketed for human consumption. The FDA added it to the Category 2 bulk drug substance list in 2023, blocking compounding pharmacies from producing it. On April 15, 2026, HHS Secretary Robert F. Kennedy Jr. removed BPC-157 and 11 other peptides from Category 2. This does not automatically legalize compounding. PCAC review begins July 2026, with earliest pharmacy access projected for late 2026 to mid-2027. BPC-157 is prohibited by WADA under category S0, both in competition and out. Athletes subject to testing should not use it. Outside the US, BPC-157 is available as a research peptide in most countries without specific regulation. It is not a controlled substance. Product quality varies; request a third-party certificate of analysis with mass spectrometry confirmation before purchasing. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Peptide Schedule Research TeamReviewed Apr 202615 Citations
